Citadel Advisors
MNPR icon

Citadel Advisors’s Monopar Therapeutics MNPR Stock Holding History

Citadel Advisors’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.2M Buy
58,436
+53,363
+1,052% +$3.22M ﹤0.01% 5134
2025
Q4 		$331K Buy
+5,073
New +$414K ﹤0.01% 9924
2025
Q3 		– Sell
-6,232
Closed -$223K – 13602
2025
Q2 		$223K Buy
+6,232
New +$226K ﹤0.01% 10455
2021
Q2 		– Sell
-2,496
Closed -$77K – 14112
2021
Q1 		$77K Buy
+2,496
New +$91.1K ﹤0.01% 12666

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's MNPR Position: Q1 2026 in Review

Citadel Advisors increased its Monopar Therapeutics (MNPR) stake by 1,052% in Q1 2026, buying an estimated $3.22M and bringing the position to 58,436 shares worth $3.2M. The position accounts for ﹤0.01% of the portfolio, ranked #5134.

Citadel Advisors first reported a position in MNPR in Q1 2021 and has held it in 4 quarters since. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Citadel Advisors held 58,436 shares of Monopar Therapeutics worth $3.2M as of Q1 2026.
  • Citadel Advisors bought 53,363 Monopar Therapeutics shares in Q1 2026, an estimated $3.22M.
  • Monopar Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5134 holding.
  • Citadel Advisors first reported a position in Monopar Therapeutics in Q1 2021 and has held it in 4 quarters since.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.